

# Advances in the treatment of prostate cancer with radiotherapy

J. Gomez-Millan<sup>a,\*</sup>, M. Fernanda Lara<sup>b</sup>, R. Correa<sup>a</sup>, A. Perez-Rozos<sup>a</sup>,  
Y. Lupiañez-Perez<sup>a</sup>, J.A. Medina<sup>a</sup>

<sup>a</sup> Department of Radiation Oncology, University Hospital Virgen de la Victoria, Malaga, Spain

<sup>b</sup> Department of Urology, University Hospital Virgen de la Victoria, Malaga, Spain

Accepted 16 February 2015

## Contents

1. Introduction .....	145
2. Intensification of radiotherapy .....	146
2.1. Dose escalation .....	146
2.2. Integration of chemotherapy with ADT and radiotherapy .....	148
3. Targeting specific molecular pathways .....	148
3.1. PI3K pathways: a critical oncogenic pathway .....	148
3.2. Tumour microenvironment .....	149
3.3. Immunotherapy .....	149
4. Patient selection .....	149
5. Conclusions .....	150
Conflict of interest .....	150
Reviewers .....	150
References .....	150
Biographies .....	152

## Abstract

**Introduction:** Prognosis of prostate cancer has improved as a result of the combination with androgen deprivation therapy and the increase of radiation dose. However, a high number of prostate cancer patients will develop biochemical recurrence; therefore a research effort to increase the control of the tumour in these patients is necessary.

**Methods:** To increase the therapeutic ratio (the index between cytotoxic effects and normal tissue complications with a certain dose of radiation), different new strategies described in the literature have been reviewed.

**Results:** There are several strategies that may increase the efficacy of radiotherapy to treat prostate cancer. First is based on physics and technology, and second based on biology.

**Discussion:** Technical advances in radiotherapy allow intensification of radiation through escalation of the dose or in combination with chemotherapy. Furthermore, targeting specific molecular dysregulated pathways in the tumour will increase the effects of radiation specifically in tumour cells. Hopefully, these strategies will result in increased rates of tumour control in all prognostic groups, especially in high risk tumours and a subgroup of patients with intermediate risk tumours, minimizing treatment morbidity and increasing the therapeutic ratio of radiotherapy.

© 2015 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** Prostate cancer; Radiotherapy; Dose escalation; Stereotactic body radiotherapy

\* Corresponding author at: Servicio de Oncología Radioterápica, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n 29010, Málaga, Spain. Tel.: +34 951032617; fax: +34 951032615.

E-mail address: [jaimegomezmillan@gmail.com](mailto:jaimegomezmillan@gmail.com) (J. Gomez-Millan).